Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Study Overview
=================
Brief Summary
-----------------
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual's medical history and program eligibility criteria.

Official Title
-----------------
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Conditions
-----------------
Prostate Cancer, NRG1, NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult, Head and Neck Cancer, Colorectal Cancer, Breast Cancer, Cholangiocarcinoma, Renal Cell Carcinoma, Unknown Primary Tumors

Intervention / Treatment
-----------------
* Drug: MCLA-128


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older At least one evaluable or measurable lesion according to RECIST v1.1 Patient with advanced metastatic solid tumor with documented NRG1 fusion determined in a qualified local laboratory by molecular profiling using methods such as next generation sequencing [DNA or RNA] or FISH as routinely performed at CLIA or other similarly-certified laboratories. Treatment with anticancer medications or investigational drugs within the following intervals before the first administration of MCLA-128: At least 14 days for chemotherapy, targeted small molecule therapy, or radiation therapy OR At least 5 half-lives have passed since discontinuation of the systemic treatment Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Adequate organ function at the time of initiation of treatment administration Negative pregnancy test results in women of childbearing potential (defined as women ≤50 years of age or history of amenorrhea for ≤12 months prior to study entry) Ability to give written, informed consent prior to treatment, with the understanding that the consent may be withdrawn by the patient at any time without prejudice Not eligible or feasible to participate in a clinical trial Any condition that in the opinion of Merus may preclude appropriate use of the investigational medicine Exclusion Criteria: Any untreated, symptomatic central nervous system (CNS) lesion Presence of an active and uncontrolled infection Leptomeningeal metastases Known hypersensitivity to any of the components of MCLA-128 or history of severe hypersensitivity reactions to human or humanized monoclonal antibodies, including therapeutic antibodies Presence of NYHA Class III or IV congestive heart failure or LVEF <50% or history of significant cardiac disease, unstable angina, congestive heart failure, myocardial infarction, or ventricular arrhythmia requiring medication Presence of any other medical or psychological condition deemed by the Physician to be likely to interfere with a patient's ability to sign informed consent, cooperate or participate in the study, or interfere with the interpretation of the results.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MCLA-128|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early Access, NRG1, Pancreas cancer, Non Small Cell Lung Cancer, Solid tumor, Compassionate use, Expanded access